[go: up one dir, main page]

WO2005112667A1 - Aliment pour la santé - Google Patents

Aliment pour la santé Download PDF

Info

Publication number
WO2005112667A1
WO2005112667A1 PCT/JP2004/006849 JP2004006849W WO2005112667A1 WO 2005112667 A1 WO2005112667 A1 WO 2005112667A1 JP 2004006849 W JP2004006849 W JP 2004006849W WO 2005112667 A1 WO2005112667 A1 WO 2005112667A1
Authority
WO
WIPO (PCT)
Prior art keywords
harmful
acid
excretion
health food
chelating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/006849
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Omori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/JP2004/006849 priority Critical patent/WO2005112667A1/fr
Priority to JP2006519161A priority patent/JPWO2005112667A1/ja
Publication of WO2005112667A1 publication Critical patent/WO2005112667A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Definitions

  • the present invention relates to a health food that excretes harmful heavy metals or harmful minerals accumulated in a human or animal body.
  • JP-A-2003-61631 discloses powdered beverages and foods containing citrate and an amino acid as main components.
  • An object of the present invention is to provide an intake of each nutrient for improving athletic performance and a compounding ratio that makes use of the characteristics of the nutrient.
  • Palin, leucine, anoreginin, isoleucine, methionine, threonine, lysine and the like, and the vitamins are vitamin 8, vitamin B1, B2, B3, B6, B12, niacin, folic acid and the like.
  • a mixture of a powdery isolated soybean protein and a powder containing anthocyanin is added to an organic compound such as citric acid, tartaric acid, and malic acid.
  • an organic compound such as citric acid, tartaric acid, and malic acid.
  • Japanese Patent Application Publication No. 9-502258 discloses a novel clinical marker, a therapeutic agent and a method of use in renal lithiasis.
  • a complex compound of metal ions such as cadmium, lead, strontium, and arsenic, including heavy metal contamination of the environment, is formed, and its concentration is reduced. Let Therefore, it is also used for treating heavy metal poisoning in the human or animal body.
  • dichenic acid cyclic ester, cunic acid is used as a starting material.
  • an automated lead assay disclosed in Japanese Patent Publication No. 9-507026 discloses a method of mixing a sample suspected of containing lead with a disulphide enzyme inhibited in the presence of lead, a substrate that reacts with the enzyme, and a fluorescer. To form an Atsey solution, to which a lead recovery agent, , A lead chelating agent such as sodium citrate is added. By measuring the amount of the enzyme-substrate reaction product, the amount of lead in the sample can be measured indirectly.
  • Patent Document 1 JP 2003-61631 A
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2002-230
  • Patent Document 3 Japanese Patent Publication No. 9-502258
  • Patent Document 4 Japanese Patent Publication No. 9-507026
  • an object of the present invention is to provide a health food that efficiently excretes harmful heavy metals or harmful minerals accumulated in the human or animal body from the human or animal body.
  • the present invention according to claim 1 comprises an essential chelating agent or a chelating agent-derived material, methylsulfonylmethane, citric acid, and L-cystine;
  • the essential chelating agent or the chelating agent-derived material is formed in a solid state or a fluid state, and the essential chelating agent or the chelating agent-derived material is ingested into a human body or an animal body, whereby the human body or the animal body has The harmful heavy metal or harmful mineral is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or harmful mineral is excreted from the human or animal body. It is a healthy food.
  • the invention of claim 2 provides malic acid, L-parin, L-leucine, L-isoleucine, phycocyanin, phytic acid, L-cystine, L-methionine, ethylenediamine, EDTA, polylipoic acid, and flavonoids.
  • At least one of a compound, tartaric acid, gnoreconic acid, and alginic acid is added, and the added chelating agent is formed into a solid or fluid, and the added chelating agent is added to the human or animal body.
  • the harmful heavy metal or harmful mineral in the human or animal body is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or the harmful mineral becomes 2.
  • the present invention according to claim 3 is the health food according to claim 2, wherein the essential chelating agent or the chelating agent-derived material, and the added chelating agent power is 0.001 to 35.0% by weight.
  • vitamin B1 vitamin B2, vitamin B6, vitamin
  • B12 comprising at least one kind of folic acid, wherein the saccharide is dalcosamine.
  • the sixth aspect of the present invention is the health food according to the first or second aspect, wherein Noji is added.
  • the present invention according to claim 7 is the health food according to claim 1 or 2, which is formed into a powder, a granule, a tablet, or a paste, or the powder or the granule is contained in a capsule.
  • the present invention according to claim 8 is characterized in that as a flavoring agent, a fruit juice extract, bontan extract, lychekis, apple juice, orange juice, citron extract, peach flavor, ume flavor, a sweetener, acesulfame K, erythritol, oligo Saccharides, mannose, xylitole, catabolized saccharides, tea components such as green tea, oolong tea, banaba tea, Tochu tea, Tei Kannon tea, noto, tom tea, amatiyaru tea, makomo tea, kelp tea, and yogurt flavor, vitamin C 3.
  • a flavoring agent a fruit juice extract, bontan extract, lychekis, apple juice, orange juice, citron extract, peach flavor, ume flavor, a sweetener, acesulfame K, erythritol, oligo Saccharides, mannose, xylitole, catabolized saccharides, tea
  • the harmful heavy metal is composed of at least one of Cd, Hg, Pb, and Cr
  • the harmful mineral is composed of at least one of Al, Be, and As. It is a health food described in 1 or 2.
  • the essential chelating agent or the chelating agent-derived material is methylsulfonylmethane, citrate, L-cystine, and the essential chelating agent or the chelating agent-derived material is solid.
  • the essential chelating agent or chelating agent-inducing substance when the essential chelating agent or chelating agent-inducing substance is ingested into the human or animal body by being formed in a fluid form, it blocks harmful heavy metals or harmful minerals in the human or animal body to chelate harmful heavy metals. Substances or toxic minerals are formed, and harmful heavy metals or harmful minerals Excreted from the body.
  • the mixing ratio of the essential chelating agent or chelating agent-derived material and the added chelating agent is selected. , Can be adjusted.
  • the health food is added with at least one of vitamins and carbohydrates.
  • vascular cells are reinforced, which is useful for preventing arteriosclerosis.
  • the vitamin comprises at least one of vitamin B1, vitamin B2, vitamin B6, vitamin B12, and folic acid, and the carbohydrate is dalcosamine.
  • vascular cells are reinforced, which is useful for preventing arteriosclerosis.
  • health food is added with Noji.
  • the health food is formed into solid powders, granules, or tablets, or the powders and granules are contained in a capsule. It is also formed into a paste that is in fluid form.
  • a flavoring agent a botan extract, a lychee extract, an apple juice, an orange juice, a yuzu extract, a peach flavor, a plum flavor, a sweetness agent, acesulfame K as a sweetener, Erythritol, oligosaccharides, mannose, xylitole, isomerized saccharides, green tea, oolong tea, banaba tea, junchu tea, iron guanyin tea, pigeon tea, amachiazul tea, makomo tea, kelp tea, yogurt flavor, vitamins One or more types of C are added.
  • a composition that does not remove the flavoring agent only for the purpose of excluding harmful heavy metals or harmful minerals is within the scope of the present invention.
  • Taste is important because administration over a medium to long term is preferable for the effectiveness of the excretion effect.
  • a flavoring agent is added to improve the taste.
  • the health food has various tastes according to the type and the amount of the flavoring agent added, the taste is improved, and the health food is easy to be used for medium- to long-term administration.
  • the harmful heavy metal is at least one of Cd, Hg, Pb, and Cr
  • the harmful mineral is at least one of Al, Be, and As.
  • Hazardous heavy metals are blocked by an essential chelating agent or chelating agent-derived material or an added chelating agent to form a toxic heavy metal chelating compound
  • harmful minerals are an essential chelating agent or a chelating agent-derived material, or an added chelating agent.
  • To form a toxic mineral chelate compound As a result, one or more of Cd, Hg, Pb, and Cr are used as chelating compounds of harmful heavy metals, and one or more of Al, Be, and As are used as chelating compounds of harmful minerals. Or it is excreted in the body of the animal.
  • a subject collects urine in the morning in the morning before the ingestion of the health food of the present invention in a cleaning plastic cup, measures the total excretion (including nocturnal urine), stores the partial urine in a PFA (fluororesin processed) container, and then ingests In the morning, in the morning and evening, the health food of the present invention was ingested according to the method of ingestion, and in the early morning of the next day, the same amount as the previous day's urine was collected and the total excreted amount was measured (including nocturnal urine). Store in FA (fluororesin processing) container.
  • FA fluororesin processing
  • Blanks should not contain biological samples.
  • Example 11-11 harmful minerals in urine and excretion of minerals in urine before and after ingestion of health foods are summarized below.
  • a normality test was performed for each data, and when the data followed a normal distribution, a paired t-test was performed. When each data did not follow the normal distribution, a Wilcoxon signed rank sum test was performed.
  • Example 1 The components of the health food in Example 1 are as follows:
  • Methylsulfonylmethane (42.5 mg), citric acid (50 mg), L-cystine (2.5 mg), malic acid (50) mg, L-parin (125) mg, L-mouth isine (125) mg , L-isoleucine (125) mg, phycocyanin (25) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (0) mg, ethylenediamine (0) mg, EDTA (0) mg , Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg, and vitamin Bl (0) mg, vitamin B2 (0) mg, Vitamin B6 (0) mg, Vitamin B12 (0) zg, folic acid (0) zg, (0) mg gnorecosamine, (0) mg noni, and the flavoring agent is grapefruit juice (50) mg, and oligosaccharide (1500) mg.
  • Example 1 as shown in Table 1, the average value of arsenic (As) was 10.22 (zg / hr) and 21.46 ( ⁇ g / hr), as shown in Figure 2. 2. One-time increase in excretion was observed. In addition, a significant difference test of these results demonstrated that there was a significant difference in p-value of 0.016 (p-0.05) in the t-test and an increase in arsenic excretion after ingestion. Similarly, when examining each harmful mineral, as shown in Table 1, the average value of mercury (Hg) was 0.106 ( ⁇ / 1 ⁇ ) and 0.160, as shown in Fig. 3. ( ⁇ / 1 ⁇ ) and about 1.5 times the amount of excretion An increase was observed.
  • Hg mercury
  • the urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • the mg and flavoring agents consist of (50) mg of orange juice and (1500) mg of oligosaccharides.
  • Example 2 the harmful mineral excretions at bedtime before and after ingestion of health foods are summarized.As shown in Table 3, the average value of arsenic (As) was 8.6 (/ ig / hr) to 18.57 ( / g / hr) and about a 2.1-fold increase in excretion. In addition, a significant difference test of the results showed that there was an increase in arsenic excretion after ingestion with a significant difference in p value of 0.0096 (p ⁇ 0.05) in the t test. Similarly, when considering also the harmful minerals, as shown in Table 3, the mercury (Hg), Mean value 0. 083 ( ⁇ 71 1 month at about a et 0. 152 (zg / hr) 1. 83 A two-fold increase in excretion was observed.
  • the excretion was increased by about 1.42 times to 00 ( ⁇ g / hr).
  • Urinary mineral excretion per hour during bedtime ig / hr.
  • Example 3 the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized. As shown in Table 5, the average value of arsenic (As) was 10 ⁇ 09 (/ ig / hr) as shown in Table 5. The excretion was increased by about 2.1 times to 19 ⁇ 60 (/ ig / hr). The Wilcoxon test also demonstrated a significant difference in arsenic excretion after ingestion.
  • the average value of cadmium (Cd) was 0.040 (zg / hr), and 0.070 ( ⁇ / 111 and mercury (13 ⁇ 4) increased about 1.8 times as much as that of mercury (13 ⁇ 4).
  • the average value of lead (Pb) increased from 0.054 (zg / hr) to 0.086 ( ⁇ g / hr), a 1.6-fold increase.
  • the urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 4 the amount of harmful mineral excretion during bedtime before and after ingestion of the health food was summarized. As shown in Table 7, the average value of arsenic (As) was 13.76 (/ ig / hr). The excretion was increased by about 1.4-fold to 19 ⁇ 34 (zg / hr). In addition, a significant difference test of the results showed that the Wilcoxon test showed a significant difference in the increase in arsenic excretion after ingestion with a significant difference. Similarly, when each harmful mineral is examined, as shown in Table 7, the average value of mercury (Hg) is 0.099 ( ⁇ / 111 mosquitoes, etc., 0.135 ( ⁇ / 111 and 1.36%).
  • the excretion was increased by 79 ( ⁇ g / hr), about 1.6 times.
  • urinary mineral excretion was increased to 9.773 (xgZhr) and 10.811 ( ⁇ g / hr) as the average value for calcium (Ca). Although there was a change of about 1.1 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
  • the urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 5 the harmful mineral excretions at bedtime before and after ingesting the health food were summarized.
  • Table 9 the average value of arsenic (As) was 8.20 (zg / hr) to 17.13 (zg / hr) and about a 2.1-fold increase in excretion.
  • a significant difference test of this result shows that the Wilcoxon test showed a significant difference in arsenic excretion after ingestion. And it was proved.
  • the average value of mercury (Hg) was 0.107 ( ⁇ / 1 ⁇ ), 0.169 ( ⁇ / 1 ⁇ ) A five-fold increase in excretion was noted.
  • the excretion of cadmium (Cd) is about 1.5 times the average from 0.050 (zg / hr) to 0.078 ( ⁇ / 111 and mercury (13 ⁇ 4)).
  • the average value of lead (Pb) was 0.059 (zg / hr), 0.082 ( ⁇ g / hr), and about 1.3 times higher. Increased excretion was observed.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • vitamin Bl (3) mg, vitamin B2 (3) mg, vitamin B6 (3) mg, vitamin B12 (3) / ig, folic acid (20) / ig, darcosamine (10) mg, and noni (10 ) mg and flavoring agents consist of (50) mg of grape juice and (1500) mg of oligosaccharides.
  • Table 6 summarizes the total excretion of harmful minerals during bedtime before and after ingesting health foods for Example 6, and as shown in Table 11, the average value of arsenic (As) was 10 ⁇ 27 (/ ig / hr). 16 The excretion was increased by about 1.6 times, 65 (/ 1 ⁇ / 1 ⁇ ). In addition, a significant difference test of the results proved that there was an increase in arsenic excretion after ingestion with a significant difference from the p-value of 0.032 (p ⁇ 0.05) in the t-test. Similarly, when examining each harmful mineral, as shown in Table 11, the average value of mercury (Hg) was 0.098 ( ⁇ ⁇ / ⁇ ) and 0.139 ( ⁇ g / hr). 1. A four-fold increase in excretion was observed.
  • the average excretion of lead (Pb) was 0.072 ( ⁇ g / hr) and 0.093 ( ⁇ g / hr). .
  • the urinary mineral excretion amount was 8.362 (/ ig / hr) and the average value was 10.689 (/ ig / hr) for calcium (Ca).
  • the increase in calories resulted in a change of about 1.3 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 7 the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized.
  • the arsenic (As) was 11.81 (/ ig / hr) was 19.5 2 ⁇ / ⁇ ), an increase of about 1.7 times in excretion.
  • a significant difference test of the results proved that there was an increase in arsenic excretion after ingestion with a significant difference of p-value of 0.010 (p-0.05) in the t-test.
  • mercury (Hg) The excretion was increased by about 193 (zg / hr), about 1.7 times.
  • urinary mineral excretion increased in calcium (Ca) by an average of 7.711 (/ ig / hr) to 11.586 (/ ig / hr). About 1.5 times However, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t-test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • citric acid 100) mg, L-cystine (2.5) mg, linoleic acid (100) mg, L-parin (50) mg, L-mouth isine (50) mg, L-isoleucine (50) mg, phycocyanin (2.5) mg, phytic acid (0) mg, L-cystine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, ⁇ —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added.
  • Example 8 the amount of harmful mineral excretion during bedtime before and after ingestion of health food was summarized.
  • the average value of arsenic (As) was 10 ⁇ 69 (/ ig / hr) An increase in excretion of about 20.24 (and about 1.9-fold was observed.
  • a significant difference test showed that the t-test showed a significant difference in p-value of 0.016 (p-0.05) after ingestion of arsenic excretion.
  • the average value of mercury (Hg) was 0.107 ( The mosquitoes were 0.182 (/ ig / hr), an increase of the excretion of about 1.7 times.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 9 the harmful mineral excretions at bedtime before and after ingesting the health food were summarized.
  • the arsenic (As) level of 8.708 (zg / hr) The amount of excretion increased by about 1.9 times, which was 16.697 ( ⁇ / ⁇ ).
  • this result It was demonstrated that there was a significant difference in the arsenic excretion after ingestion with a significant difference in the t-test.
  • the average of mercury (Hg) was 0.088 ⁇ / 1 ⁇ ) and 0.139 ( ⁇ / 1 ⁇ ). 1. 6-fold increase in non-excretion was observed.
  • the average value of cadmium (Cd) is 0.038 (zg / hr), the power is 0.064 (zg / hr), and the amount of excretion is about 1.7 times that of mercury (Hg). Increased.
  • the average excretion of lead (Pb) was 0.149 (zg / hrW 0.179 ( ⁇ g / hr)), an increase of about 1.2 times.
  • urinary mineral excretion was increased to 8.833 (g / hr) for calcium (Ca) at an average value of 7 ⁇ 281 g / hr. Although there was a change of about 1.2 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 10 the amount of harmful mineral excretion at bedtime before and after ingestion of health food was summarized. As shown in Table 19, the average value of arsenic (As) was 10.54 (/ ig / hr) The excretion was increased by about 1.9-fold to 19.70 (/ 1 ⁇ / 1 ⁇ ). In addition, a significant difference test of the results proved that there was a significant difference in the arsenic excretion after ingestion with a significant difference in the t-test.
  • urinary mineral excretion shows that calcium (Ca) has an average of 9.267 (/ ig / hr) and 10.041 (/ ig / hr). Although the increase in calories resulted in a change of about 1.1-fold, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t-test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 11 The components of the health food in Example 11 were: Methylsulfonylmethane (50) mg, citric acid (45) mg, L-cystine (5) mg, malic acid (0) mg, L_palin (0) mg, L-mouth isine (0) mg, L-isoleucine (0) mg, phycocyanin (0) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, alginic acid (0) mg, vitamin B l (10) mg, vitamin B2 ( 10) mg, vitamin B6 (10) mg, vitamin B12 (5) ⁇ g, folic acid (25) zg, (0) mg gnorecosamine, and (0) mg noni.
  • Example 11 the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized.
  • Table 21 the average value of arsenic (As) was 9.31 (zg / hr).
  • the excretion increased by about 1.3-fold from 11.90 ( ⁇ / ⁇ 11, and a significant difference test was performed.
  • the t-test (p ⁇ 0.05) showed a significant difference in the intake. It was later proved to be capable of increasing arsenic excretion.
  • mercury (Hg) an increase in excretion of about 1.3 times was observed.
  • the average value of cadmium (Cd) is 0.043 ( ⁇ g / hr) and the power is 0.064 ( ⁇ g / hr), which is about 1.5 times higher than that of mercury (Hg). Increased excretion was observed.
  • the average excretion was 0.073 g / hr, and the excretion was about 1.3 times as high as 0.092 ( ⁇ g / hr). .
  • the urinary mineral excretion amount was 9.019 (/ ig / hr) and 9.443 (/ ig / hr) in average for calcium (Ca). Increase the number of calories by about 1.04 times However, when a test similar to arsenic was performed on this result, a significant difference was not obtained in the t test. (T-test, ⁇ ⁇ 0. 05 for 0.11)
  • Intake of the health food of the present invention in daily life and in the absence of the health food increase the urinary excretion of harmful minerals with a statistically significant difference and maintain secondary health. It is considered to be a useful food for promotion.
  • Harmful heavy metals or harmful minerals that accumulate and deposit in the human body or animal body by foods and food additives and induce various health disorders and diseases are efficiently excreted from the human body or animal body, Prevent the induction of health disorders and diseases. Furthermore, it can be widely used in fields that require improvement and healing.
  • FIG. 1 is a comparison graph of total urinary lead (Pb) excretion before and after ingestion of health food.
  • FIG. 2 is a comparison graph of total urinary arsenic (As) excretion before and after ingestion of health food.
  • FIG. 3 is a comparison graph of total urinary mercury (Hg) excretion before and after intake of health food.
  • FIG. 4 is a comparison graph of the total excretion of cadmium (Cd) in urine before and after intake of health food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Aliment pour la santé lequel permet à des métaux lourds nocifs ou à des minéraux nocifs accumulés dans le corps humain ou animal d'être éliminés de façon efficace du corps. L'aliment pour la santé contient : des agents chélatant additifs comprenant du méthylsulfonylméthane, de l'acide citrique et de la L-cystéine comme agents chélatants essentiels ou des substances induisant des agents chélatants et comprenant en plus au moins un de l'acide malique, la L-valine, la L-leucine, la L-isoleucine, la phycocyanine, l'acide phytique, la L-cystéine, la L-méthionine, l'éthylènediamine, l'EDTA, l'acide α-lipoïque, des composés flavonoïdes, l'acide tartrique, l'acide gluconique et l'acide alginique ; au moins un élément parmi des vitamines et des glucides ; et un arôme. Lorsque l'aliment pour la santé est ingéré par un humain ou un animal, des composés chélates de métaux lourds nocifs ou de minéraux nocifs sont formés et les métaux lourds nocifs ou les minéraux nocifs sont éliminés du corps humain ou animal.
PCT/JP2004/006849 2004-05-20 2004-05-20 Aliment pour la santé Ceased WO2005112667A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2004/006849 WO2005112667A1 (fr) 2004-05-20 2004-05-20 Aliment pour la santé
JP2006519161A JPWO2005112667A1 (ja) 2004-05-20 2004-05-20 健康食品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2004/006849 WO2005112667A1 (fr) 2004-05-20 2004-05-20 Aliment pour la santé

Publications (1)

Publication Number Publication Date
WO2005112667A1 true WO2005112667A1 (fr) 2005-12-01

Family

ID=35428205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/006849 Ceased WO2005112667A1 (fr) 2004-05-20 2004-05-20 Aliment pour la santé

Country Status (2)

Country Link
JP (1) JPWO2005112667A1 (fr)
WO (1) WO2005112667A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006111566A (ja) * 2004-10-14 2006-04-27 Taisho Pharmaceut Co Ltd メチオニン配合内服液剤
JP2007197413A (ja) * 2006-01-28 2007-08-09 Bhn Kk 色素沈着阻害剤及びその利用
JP2007262054A (ja) * 2006-03-02 2007-10-11 Taisho Pharmaceut Co Ltd 内服液剤
JP2011512366A (ja) * 2008-02-20 2011-04-21 グノーシス・エツセ・ピー・アー 葉酸塩、これらの組成物および使用
JP2012219013A (ja) * 2011-04-04 2012-11-12 Nihon Medi Physics Co Ltd 腎臓トランスポーターの輸送能を抑制するための組成物
CN102972752A (zh) * 2012-08-21 2013-03-20 苏州谷力生物科技有限公司 一种具有排除重金属功能的组合物
CN105769843A (zh) * 2016-04-08 2016-07-20 南京师范大学 L‐茶氨酸在制备预防或治疗重金属镉引起的机体损伤药物中的应用
CN106232143A (zh) * 2014-04-02 2016-12-14 巴利阿里群岛大学 尿酸化剂和结晶抑制剂的组合制剂以及其用于治疗或预防磷酸盐或磷酸钙诱导的肾结石的应用
KR20180058251A (ko) * 2016-11-23 2018-06-01 충남태안영농조합법인 굼벵이를 이용한 체내 미네랄 균형 유지, 중금속의 생체 내 흡수 방지 및 체외 배출을 위한 기능성 식품 조성물
CN108348777A (zh) * 2015-09-30 2018-07-31 诺瓦利克有限责任公司 半氟化化合物和其组合物
KR101957502B1 (ko) * 2018-08-17 2019-03-12 이승훈 메틸설포닐메탄을 함유하는 비만, 지방간 및 당뇨병 예방 또는 개선용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59501748A (ja) * 1982-09-14 1984-10-18 ハ−シユラ−，ロバ−ト　ジエイ メチルスルホニウムメタンの医薬用途ならびにそれを含む組成物
JPS6212A (ja) * 1985-04-29 1987-01-06 ロバ−ト、ジエイ、ハ−シユラ− メチルスルホニルメタンを含む食餌製品およびその使用
JP2002080385A (ja) * 2000-06-27 2002-03-19 Hayashibara Biochem Lab Inc 金属沈着抑制剤
JP2003535126A (ja) * 2000-06-02 2003-11-25 ザ プロクター アンド ギャンブル カンパニー 定義した健康上の利益を促進する組成物、キット、及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59501748A (ja) * 1982-09-14 1984-10-18 ハ−シユラ−，ロバ−ト　ジエイ メチルスルホニウムメタンの医薬用途ならびにそれを含む組成物
JPS6212A (ja) * 1985-04-29 1987-01-06 ロバ−ト、ジエイ、ハ−シユラ− メチルスルホニルメタンを含む食餌製品およびその使用
JP2003535126A (ja) * 2000-06-02 2003-11-25 ザ プロクター アンド ギャンブル カンパニー 定義した健康上の利益を促進する組成物、キット、及び方法
JP2002080385A (ja) * 2000-06-27 2002-03-19 Hayashibara Biochem Lab Inc 金属沈着抑制剤

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006111566A (ja) * 2004-10-14 2006-04-27 Taisho Pharmaceut Co Ltd メチオニン配合内服液剤
JP2007197413A (ja) * 2006-01-28 2007-08-09 Bhn Kk 色素沈着阻害剤及びその利用
JP2007262054A (ja) * 2006-03-02 2007-10-11 Taisho Pharmaceut Co Ltd 内服液剤
JP2011512366A (ja) * 2008-02-20 2011-04-21 グノーシス・エツセ・ピー・アー 葉酸塩、これらの組成物および使用
JP2012219013A (ja) * 2011-04-04 2012-11-12 Nihon Medi Physics Co Ltd 腎臓トランスポーターの輸送能を抑制するための組成物
CN102972752A (zh) * 2012-08-21 2013-03-20 苏州谷力生物科技有限公司 一种具有排除重金属功能的组合物
CN106232143A (zh) * 2014-04-02 2016-12-14 巴利阿里群岛大学 尿酸化剂和结晶抑制剂的组合制剂以及其用于治疗或预防磷酸盐或磷酸钙诱导的肾结石的应用
US20170106032A1 (en) * 2014-04-02 2017-04-20 Universitat De Les Illes Balears Combination of a urinary acidifier and a calcium phosphate crystallisation inhibitor for the treatment or prevention of renal lithiasis
CN108348777A (zh) * 2015-09-30 2018-07-31 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN108348777B (zh) * 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN105769843A (zh) * 2016-04-08 2016-07-20 南京师范大学 L‐茶氨酸在制备预防或治疗重金属镉引起的机体损伤药物中的应用
KR20180058251A (ko) * 2016-11-23 2018-06-01 충남태안영농조합법인 굼벵이를 이용한 체내 미네랄 균형 유지, 중금속의 생체 내 흡수 방지 및 체외 배출을 위한 기능성 식품 조성물
KR101957502B1 (ko) * 2018-08-17 2019-03-12 이승훈 메틸설포닐메탄을 함유하는 비만, 지방간 및 당뇨병 예방 또는 개선용 조성물
WO2020036257A1 (fr) * 2018-08-17 2020-02-20 이승훈 Composition contenant du méthyl sulfonyl méthane destinée à prévenir ou à soulager l'obésité, la stéatose hépatique et le diabète
JP2021535121A (ja) * 2018-08-17 2021-12-16 リー, スン フンLEE, Seung Hoon メチルスルフォニルメタンを含有する肥満、脂肪肝及び糖尿病予防または改善用組成物

Also Published As

Publication number Publication date
JPWO2005112667A1 (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
Walker et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study
Bodnar et al. Methods of selenium supplementation: bioavailability and determination of selenium compounds
Javad et al. Analysis of aluminum, minerals and trace elements in the milk samples from lactating mothers in Hamadan, Iran
de Souza et al. Determination of total concentration and bioaccessible fraction of metals in infant cereals by MIP OES
Obara et al. Isohumulones, the bitter component of beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes
Keßler et al. Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects
WO2005112667A1 (fr) Aliment pour la santé
Marrero et al. Inductively coupled plasma optical emission spectrometric determination of fifteen elements in dietary supplements: are the concentrations declared in the labels accurate?
Patriarca et al. Atomic spectrometry update: review of advances in the analysis of clinical and biological materials, foods and beverages
EP2271367B1 (fr) Accélérateur d'absorption de minéraux et agent ou composition alimentaire améliorant l'anémie ferriprive
Demir et al. Estimated daily intake and health risk assessment of toxic elements in infant formulas
CN105395565B (zh) 人参皂苷f2的肝病预防或治疗用途
Rodgers et al. Do teas rich in antioxidants reduce the physicochemical and peroxidative risk factors for calcium oxalate nephrolithiasis in humans? Pilot studies with Rooibos herbal tea and Japanese green tea
Oloyede et al. Elemental composition of marketed milk from Nigeria and Brazil using ICP-OES: Health risk assessment study
KR101171068B1 (ko) 미네랄 조성물을 유효 성분으로 함유하는 당뇨 개선 및 예방용 약학적 조성물
Wojcieszek et al. Study of bioaccessibility of cobalt species in berries and seeds by mass spectrometry techniques
Erdemir et al. Correlation of lithium bioaccessibility from tea (Camellia sinensis L.) with tea type and consumption habits
JP7038424B2 (ja) 生活習慣病の改善又は予防用食品組成物
He et al. Breast milk selenocystine as a biomarker for selenium intake in lactating women at differential geographical deficiency risk in China
Cilliers et al. Multi-element analysis of brain regions from South African cadavers
Kolawole et al. Relationship between soil contents and plasma levels of selenium, chromium and manganese in healthy adult Nigerians
JP2003189818A (ja) ホヤの粉末を含む機能性食品および健康食品
Bilandžić et al. Comparative study of iron, magnesium and zinc and daily intakes in certain meats and meat products
Rungraung et al. A dose-escalation study for identifying safe doses of coffee cherry pulp juice concentrate in healthy subjects
Akter et al. Physio-biochemical changes in goats due to arsenic induced toxicity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006519161

Country of ref document: JP

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase